Belite Bio, Inc. · NASDAQ:BLTE
Belite Bio — Investor Presentation (July 2022)
17 slides from Belite Bio's investor presentation, July 2022
Slide 1: Slowing the Progression of Macular Degeneration
Slowing the Progression of Macular Degeneration Mission for Vision Media and Investor Relations Contact: Jennifer Wu /ir@belitebio.com Tim McCarthy /tim@lifesciadvisors.com BELITE BIO / 1
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Belite Bio, Inc (the “Company”) solely for information purposes. This presentation does not constitute an offer to sell or issue or the solicitation of an offer to buy or acquire securities of the Company in any jurisdiction or an inducement to enter
Slide 3: At-a-Glance
At-a-Glance “Bringing Hope to Incurable Blindness” As of 2022/7/21 Belite Bio, Inc Share Symbol BLTE Stock Exchange NASDAQ Stock Price $ 41.51 Shares Outstanding 24.87 million Market Cap $ 1,032.35 million BELITE BIO / 3
Slide 4: Leadership
Leadership Management Tom Lin, MMED, PhD, MBA Nathan Mata, PhD Jane Chiu, MS H.Y. Chuang, CFA, MBA, FRM (Chairman, CEO) (CSO) (VP, Clinical Operations) (CFO) • 10 years of executive management role • 15+ years of ophthalmic drug • 25 years clinical operations experience • 11 years of capital market
Slide 5: Belite Bio Opportunity
Belite Bio Opportunity • Belite Bio’s lead asset LBS-008 is a novel, orally administered, Retinol Binding Protein 4 (“RBP4”) antagonist intended to slow or halt progression of vision loss in Stargardt disease (STGD1) and dry AMD. A Phase 3 trial has been initiated in adolescent STGD1 patients and a
Slide 6: Board of Directors
Board of Directors Board Clinical Advisory Board Tom Lin, MMED, PhD, MBA John M. Longo, PhD Gary C. Biddle, PhD, CPA Ita Lu Dr. Frank Holz Dr. Michel Michaelides Dr. Quan Nguyen (Chairman, CEO) (Independent Director) (Independent Director) (Independent Director) • Prof. of Rutgers Business • Prof. o
Slide 7: Zero Approved Treatments
LBS LIGHT TO INCURABLE BLINDESS 008 For Dry Age-Related Macular Degeneration & Stargardt Disease DISCOVERY PRE-CLINICAL KEY OPPORTUNITY Dry AMD MARKET STGD1 MARKET Zero Approved 11M 1 in 10,000 PHASE I PHASE II Treatments PHASE III dry AMD patients in inherited juvenile onset MARKET the US (90% AMD
Slide 8: Overview of Stargardt Disease & Dry AMD
Overview of Stargardt Disease & Dry AMD LBS 008 Stargardt Disease (STGD1) • The most common inherited retinal dystrophy (blurring or loss of central vision) in both adults and children • Caused by a dysfunctional retina-specific gene (ABCA4) which causes massive accumulation of toxic vitamin A bypro
Slide 9: Similar Pathophysiology in STGD1 & Dry AMD
LBS Similar Pathophysiology in STGD1 & Dry AMD 008 • STGD1 and dry AMD share STGD1: LATE-ONSET (61-YEAR OLD FEMALE) a similar pathophysiology characterized by excessive accumulation of cytotoxic bisretinoids, retinal cell death, and loss of vision • Vision loss occurs slowly, despite peripheral Dry
Slide 10: Clear Clinical Development Pathway
Clear Clinical Development Pathway LBS 008 Reduction in Lesion Growth Rate as Measured by Retinal Imaging is an FDA Accepted Primary Endpoint in STGD1 and dry AMD completed ongoing planned Phase 1b/2 Phase 3 STGD Phase 2/3 Dry AMD Phase 1 Adolescent Adolescent NDA Dry AMD NDA STGD STGD PRV • Complet
Slide 11: Clinical Data
Clinical Data BELITE BIO / 11
Slide 12: Interim Phase 2 Results: Summary of Related Adverse Events
Interim Phase 2 Results: LBS 008 Summary of Related Adverse Events Relationship to Frequency Adverse Events Severity % Recovered % On-going Drug (#patients) Xanthopsia Mild Definitely Related 6/13 3/6 (50%) 3/6 (50%) Delayed Dark Adaptation Mild Definitely Related 8/13 1/8 (12.5%) 7/8 (87.5%) Night
Slide 13: Interim Phase 2 Data: Change in DDAF in Adolescent STGD1 Subjects
LBSInterim Phase 2 Data: Change in DDAF in Adolescent 008 STGD1 Subjects 92.3% 12 of 13 subjects showed no lesion growth 7.7% DDAF, or lesion (“dead retina”) in 1 of 13 subjects had STGD1 patient as measured by lesion growth of 0.3 retinal imaging. This is the area mm² in both eyes where retinal cel
Slide 14: Interim Phase 2 Data: Change in QDAF in Adolescent STGD1 Subjects
LBSInterim Phase 2 Data: Change in QDAF in Adolescent 008 STGD1 Subjects Distribution of Change in QDAF 23.0% 3/13 in one eye - Reduction or no change in 1 eye - Reduction or no change in both eyes - Increase in both eyes 5/13 5/13 in both eyes Areas of QDAF progressively evolve into ‘dead retina’.
Slide 15: Interim Phase 2 Results: Change of Vision in Adolescent STGD1 Subjects
Interim Phase 2 Results: Change of Vision in Adolescent LBS 008 STGD1 Subjects Change in BCVA BCVA gain in 8 of 13 Subjects (61.5%) 46.1 % 6/13 - Letter gain in 1 eye in one eye - Letter gain in both eyes - Letter decrease 5/13 2/13 Best-Corrected Visual Acuity (BCVA) Test 38.5% in both Provides let
Slide 16: Investment Highlights
Investment Highlights • LBS-008 is a novel oral treatment intended to slow or halt disease progression in both dry AMD and STGD1. • Clear Clinical Pathway: • LBS-008 continues to be well-tolerated. • Ongoing 2-year Phase 2 trial (6 months of reported interim safety data and preliminary efficacy data
Slide 17: Thank You
Thank You Media and Investor Relations Contact: Jennifer Wu /ir@belitebio.com Tim McCarthy /tim@lifesciadvisors.com For more info please visit: www.belitebio.com